Search results

Order by most recent / most popular / relevance

Results: 1-10 of 34

Universities abroad experiment with no-fee licensing to drive biotech partnerships

Shook Hardy & Bacon LLP
-
Australia, Canada, European Union, United Kingdom, USA
-
May 16 2013

Universities in Australia, Canada, Europe, and the United Kingdom have reportedly embraced a 2010 Glasgow University initiative under which companies

Dispelling the Myriad gene patent harmonization myth

Foley & Lardner LLP
-
Australia, Canada, European Union, France, Germany, Japan, USA
-
April 30 2013

In the wake of the Supreme Court oral arguments in the Myriad "gene patent" case, most commentators are predicting that the Court will uphold the

Healthcare & life sciences private equity deal tracker: Argon Medical Devices completes acquisition of Angiotech Pharmaceuticals subsidiary

McGuireWoods LLP
-
Canada, USA
-
May 8 2013

Argon Medical Devices has completed its acquisition of the interventional products business of Angiotech Pharmaceuticals Inc., according to a news

Securing IP in stem cells

Bereskin & Parr LLP
-
Canada, USA
-
April 12 2013

Stem cells are at the centre of research into regenerative medicine. They have the ability to continuously produce newly differentiated cells and

Dental investing filling need for PE investing - Part I

McGuireWoods LLP
-
Canada, USA
-
April 24 2012

Dental practice management companies have been an increasing focus of private equity firms throughout the United States and Canada

Northern exposure?

Gowling Lafleur Henderson LLP
-
Canada, USA
-
April 4 2013

Davit Akman and John Norman suggest that a recently commenced investigation into alleged "product switching" and statements by the Interim

Biosimilar battlegrounds - what is new in biosimilars and where?

Bereskin & Parr LLP
-
Canada, European Union, USA
-
February 17 2012

Biosimilars are second entry biologic drugs

Legal - or what?

Torys LLP
-
Canada, USA
-
April 17 2012

"How can you manage issues arising from regulations and legal requirements in different jurisdictions."

“Read it and weep!” - is restaurant calorie disclosure an effective behaviour modification tool?

Cassels Brock & Blackwell LLP
-
Canada, USA
-
May 17 2012

A report recently published by a Canadian advocacy group, the Centre for Science in the Public Interest (“CSPI”), titled Writing on the Wall: Time to Put Nutrition Information on Restaurant Menus, has taken on the highly debated issue of restaurant menu calorie disclosure, advocating the listing of calorie counts and sodium levels next to every menu item

The U.S. Prometheus decision and claims to methods of optimizing dosing regimens: Mayo Collaborative Services v. Prometheus Laboratories, Inc., U.S., No. 10-1150

Gowling Lafleur Henderson LLP
-
Canada, USA
-
April 11 2012

In a decision last month, the U.S. Supreme Court in a 9-0 ruling has held that the method claims of two patents directed to optimizing the dose of a specific drug for treating an autoimmune disease are not patentable because they merely recite laws of nature

next >

Search results

Universities abroad experiment with no-fee licensing to drive biotech partnerships

Dispelling the Myriad gene patent harmonization myth

Healthcare & life sciences private equity deal tracker: Argon Medical Devices completes acquisition of Angiotech Pharmaceuticals subsidiary

Securing IP in stem cells

Dental investing filling need for PE investing - Part I

Northern exposure?

Biosimilar battlegrounds - what is new in biosimilars and where?

Legal - or what?

“Read it and weep!” - is restaurant calorie disclosure an effective behaviour modification tool?

The U.S. Prometheus decision and claims to methods of optimizing dosing regimens: Mayo Collaborative Services v. Prometheus Laboratories, Inc., U.S., No. 10-1150

Current Search

Suggested Facets

Author

Firm Name

Jurisdiction

Workarea